RNS60 aids mitochondria health, protects motor neurons in ALS mice

A treatment candidate from Revalesio named RNS60 protected motor neurons from damage in a mouse model of amyotrophic lateral sclerosis (ALS) linked with accumulating toxic TDP-43 protein clumps. It also showed it could improve the health of mitochondria, the cells’ powerhouses that are abnormal in ALS, and reduce…

Short course of treatment with RNS60 extends survival in ALS

A short course of treatment with Revalesio‘s RNS60 as an add-on to standard amyotrophic lateral sclerosis (ALS) therapies extended the median survival of people with the progressive disease by about six months compared with a placebo. That’s according to up to six years of…

FDA Awards Fast Track Status to Revalesio’s RNS60 for ALS; Phase 2 Trial Recruiting

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Revalesio’s experimental therapy RNS60 for people diagnosed with amyotrophic lateral sclerosis (ALS). A phase 2 trial is now recruiting participants. Fast Track designation is intended to shorten the time it takes for the…

FDA Grants Orphan Drug Status to RNS60 for ALS Treatment

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies targeting rare and serious diseases, providing marketing exclusivity for…